Home/Pipeline/APHEXDA® (motixafortide)

APHEXDA® (motixafortide)

Stem cell mobilization in multiple myeloma

ApprovedCommercial

Key Facts

Indication
Stem cell mobilization in multiple myeloma
Phase
Approved
Status
Commercial
Company

About Gamida Cell

Gamida Cell pioneers nicotinamide-enhanced allogeneic cell therapies for hematologic conditions, with two FDA-approved products for transplantation and stem cell mobilization.

View full company profile

Therapeutic Areas